Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study

Carmen D. Herling, Kevin R. Coombes, Axel Benner, Johannes Bloehdorn, Lynn L. Barron, Zachary B. Abrams, Tadeusz Majewski, Jolanta E. Bondaruk, Jasmin Bahlo, Kirsten Fischer, Michael Hallek, Stephan Stilgenbauer, Bogdan A. Czerniak, Christopher C. Oakes, Alessandra Ferrajoli, Michael J. Keating, Lynne V. Abruzzo

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study'. Together they form a unique fingerprint.

Medicine & Life Sciences